Work

Cenobamate in brain tumor‐related epilepsy: A multicenter real‐world experience

Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,120
OpenAlex ID: W7234566140
FWCI:
Cites: 23
Cited by:
Related to: 10